Sarepta Therapeutics Newsroom

Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsDec 21 02:40

Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

TipRanksDec 21 01:56

Sell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys Projections

TipRanksDec 21 01:31

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

BenzingaDec 19 20:20

Sarepta Therapeutics Analyst Ratings

BenzingaDec 19 20:18

Sarepta Therapeutics Analyst Ratings

BenzingaDec 3 20:48

Sarepta Therapeutics Is Maintained at Sell by HC Wainwright & Co.

Dow JonesDec 3 20:09

H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $75

Futu NewsDec 2 23:32

Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks

TipRanksDec 2 23:19

BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsDec 2 20:32

Sarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth Potential

TipRanksDec 2 20:17

A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $215

Futu NewsNov 28 21:01

RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)

TipRanksNov 28 10:03

Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler

Dow JonesNov 28 00:37

A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217

Futu NewsNov 27 21:02

Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen

TipRanksNov 27 20:38

Sarepta Therapeutics Analyst Ratings

BenzingaNov 27 20:06

Sarepta Therapeutics Receives Buy Rating From Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential

TipRanksNov 27 19:08

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $202

BenzingaNov 27 18:41

Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target

TipRanksNov 27 18:28